HEALing Communities Study
Opioid Use Disorder (OUD)
About this trial
This is an interventional health services research trial for Opioid Use Disorder (OUD) focused on measuring opioid, Opioid Use Disorder (OUD), overdose, addiction, Naloxone, Buprenorphine, methadone, evidence-based practices, community engagement
Eligibility Criteria
Inclusion Criteria:
- The community must be located in one of the four participating states: Kentucky, Ohio, Massachusetts, or New York.
- At least 30% of the communities selected within each state must be rural.
- Across all the HCS communities within each state, there must be a minimum of 150 opioid-related overdose fatalities (with at least 22 opioid-related overdose fatalities experienced by the rural communities) and a rate of at least 25 opioid-related overdose fatalities per 100,000 persons, based on 2016 data.
- The community must express willingness to address in their response strategy the implementation of MOUD, overdose prevention training, and naloxone distribution across their community.
- The community must express willingness to develop partnerships across health care, behavioral health, and justice settings for evidence-based practices to address opioid misuse, OUD, and overdoses.
Exclusion Criteria:
- Communities that did not meet the aforementioned inclusion criteria were excluded from the HCS.
Sites / Locations
- University of Kentucky
- Boston Medical Center
- Columbia University
- Ohio State University
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Wave 1 - Intervention
Wave 2 - Wait-list comparison
Communities in Wave 1 will receive the CTH intervention during the first 30 months of the trial. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
Communities in Wave 2 will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.